Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
NCT05712889
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
29
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
VIP236 (Q3W)
DRUG:
VIP236 (Q2W)
Sponsor
Vincerx Pharma, Inc.